Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with a poor
prognosis, with a 3-month mortality rate of over 50%. To date, no treatment has been proven
to be effective in AI-FPI. The interest of glucocorticoids is controversial and needs to be
confirmed. This confirmation is mandatory to validate the improvement of the prognosis of
EA-IPF under this treatment but also to search for unsuspected deleterious effects as it has
been shown with immunosuppressants in stable idiopathic pulmonary fibrosis.